Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction - a Randomized, Double Blind, Placebo Controlled Study.
Phase of Trial: Phase II
Latest Information Update: 08 May 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 08 May 2016 Results assessing inflammation and secondarily reduce troponin T (TnT) release published in the European Heart Journal
- 02 Sep 2015 Primary endpoint (AUC for high-sensitive CRP) has been met.